Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease

ConclusionAs the number of new biological therapies increase in IBD, identifying patients who are most likely to benefit from specific agents is of paramount importance to help best position IBD therapies.

Source: Alimentary Pharmacology and Therapeutics - February 12, 2018 Category: Drugs & Pharmacology Authors: A. Barr é, J.‐F. Colombel, R. Ungaro Tags: REVIEW ARTICLE Source Type: research